Journal of Evaluation in Clinical Practice

Negative effect of fatty liver on visualization of pancreatic cystic lesions at screening transabdominal ultrasonography

Early View

  • Author(s): Kazuhiro Kashiwagi, Takashi Seino, Kanako Makino, Ryoko Shimizu‐Hirota, Michiyo Takayama, Toshifumi Yoshida, Eisuke Iwasaki, Yoshinori Sugino, Nagamu Inoue, Yasushi Iwao, Takanori Kanai
  • Article first published online: 22 Apr 2019
  • DOI: 10.1111/jep.13138
  • Read on Online Library
  • Subscribe to Journal

Abstract Rationale, aims, and objectives The aim of this observational study is to identify factors by which some pancreatic cystic lesions (PCLs) were undetectable at transabdominal ultrasonography (TAUS), using magnetic resonance imaging (MRI) as reference standard. Methods The database for 781 consecutive subjects who underwent a health checkup including fat computed tomography and upper abdominal MRI as option was searched. The presence of fatty liver and fatty pancreas was diagnosed by TAUS, and atrophic pancreas was determined by reevaluating the image of the pancreas in the chest computed tomography for screening. Subjects with PCL detected and those undetected at TAUS were statistically compared in clinical characteristics. Results The prevalence of PCL detected at MRI was 17.8% in the general population. Multivariate logistic regression analysis showed that fatty liver, body mass index, and the size of PCL were significantly associated with the factors influencing the visualization of PCL at TAUS (odds ratio [OR]: 0.337, 95% confidence interval [CI]: 0.154‐0.734, P = 0.006; OR: 0.852, 95% CI: 0.737‐0.985, P = 0.030; OR:1.120, 95% CI: 1.045‐1.200, P = .001). Thirty‐six PCLs (64.3%) in a total of 56 PCLs were undermeasured by TAUS. Additionally, nine (56%) out of 16 PCLs (≥ 15 mm) were undermeasured by 5 mm or more by TAUS, although a significantly higher detection rate was observed for PCLs (≥ 15 mm) in comparison with that for PCLs (< 15 mm) (80% vs 33.6%, P = .000). Conclusions It should be noted that coexisting fatty liver may lower the detection of PCL, and its size may be underestimated by TAUS.

Related Topics

Related Publications

Related Content

Site Footer


This website is provided by John Wiley & Sons Limited, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ (Company No: 00641132, VAT No: 376766987)

Published features on are checked for statistical accuracy by a panel from the European Network for Business and Industrial Statistics (ENBIS)   to whom Wiley and express their gratitude. This panel are: Ron Kenett, David Steinberg, Shirley Coleman, Irena Ograjenšek, Fabrizio Ruggeri, Rainer Göb, Philippe Castagliola, Xavier Tort-Martorell, Bart De Ketelaere, Antonio Pievatolo, Martina Vandebroek, Lance Mitchell, Gilbert Saporta, Helmut Waldl and Stelios Psarakis.